Drug Trial Radar · NCT04698642
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
Last checked: Nov 19, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Feb 3, 2020
Primary completion
Nov 12, 2020
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Phase 2a component of the study will be a randomized, open-label, parallel, and multiple dose study to further examine the safety and efficacy profile of 3 CBL-514 dose levels based on the results from Phase 1 of the study.
Conditions
- Subcutaneous Fat
Interventions
CBL-514Drug
Both sides of the abdominal region will receive CBL-514.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of abdominal subcutaneous fat volumeTime frame: Up to 8 weeks after last treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.